Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received clinical trial approval from the National Medical Products Administration (NMPA) for its 18F-LNC1007 injection, a novel radioactive diagnostic drug. This drug is designed to target fibroblast activating protein (FAP) and integrin alpha-v beta-3, which are biomarkers for diagnosing FAP and alpha-v beta-3 positive adult solid tumors. The 18F-LNC1007 injection is developed to enhance tumor uptake time, targeting efficiency, and to provide superior imaging quality for tumors. Preliminary data from preclinical and clinical translational studies indicate that the drug significantly improves these parameters, offering a promising advancement in the diagnostic toolkit for oncology.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
